Table 4 Observed cancer cases for the female Lynch syndrome cohort with 100% or 50% probability of MMR mutation (excluding colorectal and endometrial cancer)
From: A retrospective study of extracolonic, non-endometrial cancer in Swedish Lynch syndrome families
Primary cancer | Observed number | Proportion [%] | LL 95% | UL 95% | Proportion [%] in Sweden 1970 | Proportion [%] in Sweden 2010 | Reference outside CI |
|---|---|---|---|---|---|---|---|
Breast | 58 | 21.17 | 16.42 | 26.28 | 31.79 | 43.61 | below |
Ovary and Fallopian tube | 42 | 15.33 | 11.31 | 19.71 | 9.51 | 3.8 | above |
Kidney/urinary tract excl prostate | 41 | 14.96 | 10.95 | 19.34 | 5.25 | 3.34 | above |
Stomach | 29 | 10.58 | 6.93 | 14.23 | 4.47 | 1.11 | above |
Skin excluding melanoma | 24 | 8.76 | 5.47 | 12.41 | 1.37 | 4.4 | above |
Cervix | 20 | 7.3 | 4.38 | 10.58 | 10.72 | 3.71 | No |
Brain and nervous system | 12 | 4.38 | 2.19 | 6.93 | 4.58 | 4.5 | No |
Blood and lymphatic tissue | 11 | 4.01 | 1.82 | 6.57 | 7.45 | 6.81 | below |
Small bowel | 8 | 2.92 | 1.09 | 5.11 | 0.38 | 0.4 | above |
Liver and biliary system | 7 | 2.55 | 0.73 | 4.74 | 2.87 | 1.34 | No |
Lung and airways | 5 | 1.82 | 0.36 | 3.65 | 3.03 | 5.95 | No |
Pancreas | 4 | 1.46 | 0.36 | 2.92 | 2.38 | 1.58 | No |
Malignant melanoma | 4 | 1.46 | 0.36 | 2.92 | 3.8 | 8.63 | below |
Thyroid | 3 | 1.09 | 0 | 2.55 | 2.01 | 2.59 | No |
Oesophagus | 2 | 0.73 | 0 | 1.82 | 0.37 | 0.31 | No |
Bone and soft tissue | 2 | 0.73 | 0 | 1.82 | 1.16 | 0.71 | No |
Head and neck | 1 | 0.36 | 0 | 1.09 | 1.68 | 1.92 | below |
Endocrine cancer | 1 | 0.36 | 0 | 1.09 | 2.44 | 2.09 | below |